Related Experiment Videos
PF9404C, a new slow NO donor with beta receptor blocking properties
M Villarroya1, C J Herrero, A Ruíz-Nuño
1Departamento de Farmacología, Instituto de Farmacología Teófilo Hernando, Facultad de Medicina, Universidad Autónoma de Madrid, c/Arzobispo Morcillo, 4, 28029 Madrid, Spain.
British Journal of Pharmacology
|December 10, 1999
Summary
PF9404C, a novel beta-blocker, demonstrates potent vasodilatory effects by releasing nitric oxide (NO) and exhibits beta-adrenergic blocking activity. This dual mechanism suggests potential antihypertensive and cardioprotective actions.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Medicinal Chemistry
Background:
- Beta-adrenergic receptors play a crucial role in regulating heart rate and blood pressure.
- Vasodilators are essential for managing cardiovascular conditions like hypertension.
- Novel therapeutic agents with dual mechanisms of action are sought for improved efficacy.
Purpose of the Study:
- To characterize the pharmacological properties of PF9404C, a novel S-S diesteroisomer.
- To investigate its vasodilatory effects and mechanism of action.
- To evaluate its beta-adrenergic blocking activity and potential therapeutic applications.
Main Methods:
- In vitro studies using rat aorta helical strips and guinea-pig left atrium.
- Measurement of cyclic GMP formation in rat aorta smooth muscle cells.
- Radioligand binding assays using rat brain membranes.
- Concentration-response curve analysis and IC50 determinations.
Main Results:
- PF9404C induced concentration-dependent relaxation of rat aorta, comparable to nitroglycerin.
- Vasorelaxation was mediated by nitric oxide (NO) generation, as evidenced by inhibition with oxyhaemoglobin, methylene blue, and ODQ.
- PF9404C demonstrated potent beta-adrenergic receptor blockade in cardiac tissue and brain membranes.
- It significantly increased cyclic GMP levels in smooth muscle cells, unlike other beta-blockers.
Conclusions:
- PF9404C is a potent vasorelaxant and a beta-adrenergic receptor blocker.
- Its vasodilatory mechanism involves the slow generation of NO.
- The dual action of NO donation and beta-blockade positions PF9404C as a promising candidate for treating hypertension and cardiovascular diseases.